Rational design of metabolically stable HDAC inhibitors: An overhaul of trifluoromethyl ketones
作者:Banerjee Riddhidev、Karaj Endri、Lamichhane Sabitri、N. Kotsull, Lauren、Kuganesan Nishanth、Isailovic Dragan、Pflum Mary Kay H、Slama James、Taylor William、Tillekeratne L. M. Viranga
DOI:10.1016/j.ejmech.2022.114807
日期:2022.12
regulation of gene expression using histone deacetylase (HDAC) inhibitors is a promising strategy for developing new anticancer agents. The most common HDAC inhibitors are hydroxamates, which, though highly potent, have limitations due to their poor pharmacokinetic properties and lack of isoform selectivity. Trifluoromethylketones (TFMK) developed as alternatives to hydroxamates are rapidly metabolized to inactive
使用组蛋白脱乙酰酶 (HDAC) 抑制剂对基因表达进行表观遗传调控是开发新型抗癌药物的一种有前景的策略。最常见的 HDAC 抑制剂是异羟肟酸盐,虽然其效力很高,但由于其药代动力学特性较差且缺乏同工型选择性而具有局限性。作为异羟肟酸替代品而开发的三氟甲基酮(TFMK)在体内迅速代谢为无活性的三氟甲醇,这阻碍了它们作为潜在候选药物的进一步发展。为了克服这一限制,我们设计了三氟丙酮酰胺(TFPA)作为 TFMK 替代品。酮羰基旁边额外的吸电子基团的存在使得酮的水合物形式更加稳定,从而防止其在体内代谢还原为醇。此外,这种结构修饰降低了 TFMK 基团作为共价弹头消除脱靶效应的潜力。抑制剂帽基团的额外结构变化使得类似物在细胞毒性测定中的IC 50值范围从高纳摩尔到低微摩尔,并且它们对癌细胞比正常细胞更具选择性。一些最活跃的类似物以低纳摩尔 IC 50值抑制 HDAC 酶,并且被发现对 HDAC8 比